ArticleJournal of hematology & oncology2014

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.

Seiichi Okabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.